Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-09-18 Share Issue/Capital Cha…
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Début des négociations des actions issues du regroupement
Share Issue/Capital Change Classification · 1% confidence The document is a press release ("Communiqué de presse") announcing the start of trading for shares resulting from a share consolidation (regroupement d'actions). This action involves a change in the capital structure (1 new share for 5,000 old shares) authorized by the shareholders' meeting. This directly relates to changes in the company's capital structure and financing activities. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP), as it details a specific corporate action affecting the share count and structure. It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2023-09-18 French
Information relative au nombre total de droits de vote et d'actions composant le capital social et à la valeur nominale des actions
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and its primary content is the official disclosure of the total number of voting rights and shares comprising the share capital as of August 31, 2023, referencing French commercial code (Article L.233-8 II du Code de commerce) and AMF regulations (article 223-16 du Règlement général de l'Autorité des Marchés Financiers). This specific type of mandatory periodic disclosure regarding the share structure and voting rights is typically classified under announcements related to capital changes or major shareholding notifications, but the most precise fit among the provided codes for a mandatory disclosure detailing the total number of shares and voting rights is often related to capital structure updates or major shareholding changes. Given the explicit focus on the total number of shares and voting rights, this aligns closely with announcements concerning the capital structure. The code 'SHA' (Share Issue/Capital Change) is the most appropriate fit for a formal declaration of the total share count, which is a fundamental aspect of the capital structure. It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it pertains to a very specific, recurring capital structure update.
2023-09-06 French
PHARNEXT : Levée de fonds de 0,5 million d'euros
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific financial transaction: a "Levée de fonds de 0,5 million d'euros" (Fundraising of 0.5 million euros) via the issuance of OCEANE-BSA instruments. This directly relates to the company's financing activities and capital structure changes. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), but the substance of the document is the financing event itself.
2023-08-29 French
Pharnext annonce la fin de l'essai PREMIER, étude clinique pivot de Phase III en double aveugle de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a significant operational milestone: the completion of the last patient visit in the double-blind period of the PREMIER Phase III clinical trial for PXT3003. It details the trial status, patient numbers, and sets an expectation for preliminary results in Q4 2023. This type of announcement, focusing on clinical trial progress and setting expectations for future results, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing key operational/clinical progress rather than a full financial report (10-K, IR) or a transcript (CT), and it is not specifically about management changes (MANG) or dividends (DIV), it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory filing. Given the content focuses on clinical trial status and future result announcements, ER is the most appropriate fit among the provided options for a major operational update released via press release.
2023-08-24 French
Pharnext reports the end of double-blind treatment in PREMIER trial, the pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A
Earnings Release Classification · 1% confidence The document is a press release announcing a significant clinical trial milestone: the completion of the double-blind treatment period for the pivotal Phase III clinical trial (PREMIER) of PXT3003 for CMT1A. It provides details on patient numbers, trial design, next steps (topline results expected Q4 2023), and quotes from management. This type of announcement, focusing on clinical progress and upcoming data releases, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a formal announcement of operational/clinical progress, it aligns best with the 'Earnings Release' category, which often includes key operational highlights preceding formal financial filings. It is not a specific regulatory filing like DIRS or DIV, nor is it a presentation (IP) or a factsheet (FS). Given the focus on trial completion and upcoming results, ER is the most appropriate fit among the provided options for a major corporate update. Q4 2023
2023-08-24 English
Information relative au nombre total de droits de vote et d'actions composant le capital social et à la valeur nominale des actions
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and its primary content details the "Information relative au nombre total de droits de vote et d'actions composant le capital social" (Information relating to the total number of voting rights and shares comprising the share capital) as of July 31, 2023, referencing French commercial code and AMF regulations (Article L.233-8 II du Code de commerce et article 223-16 du Règlement général de l'Autorité des Marchés Financiers). This type of mandatory periodic disclosure regarding the total number of shares and voting rights is a standard regulatory filing in France, often released monthly or quarterly. It does not fit the specific definitions for 10-K (Annual Report), ER (Earnings Release), IR (Interim Report), or DIV (Dividend Notice). Given the nature of the content—a formal announcement of share capital structure updates required by market regulators—it best fits the general category of 'Regulatory Filings' (RNS) or potentially a specific capital structure update, but RNS is the most appropriate general regulatory category when a more specific one like SHA (Share Issue/Capital Change) isn't explicitly about a new issue, but rather a periodic count. Since it is a formal, required disclosure of capital structure data, and not a presentation (IP), a management discussion (MDA), or a specific transaction report (POS/SHA), RNS serves as the best fit for a general regulatory update announcement.
2023-08-01 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.